1
|
Toscano-Guerra E, Maggio V, García J, Semidey ME, Celma A, Morote J, de Torres I, Giralt M, Ferrer-Costa R, Paciucci R. Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures, and serum samples from a Spanish Caucasian population. Front Oncol 2024; 14:1398411. [PMID: 39193388 PMCID: PMC11347290 DOI: 10.3389/fonc.2024.1398411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2024] [Accepted: 07/22/2024] [Indexed: 08/29/2024] Open
Abstract
Background Prostate cancer (PCa) is a leading cause of cancer-related deaths in European men, emphasizing the urgent need for effective risk assessment strategies. The TP53 gene, a tumor suppressor gene frequently mutated in cancer, commonly harbors the rs1042522 single nucleotide polymorphism (SNP), known as the P72R SNP, which may influence PCa susceptibility. This study investigated the prevalence of the P72R SNP in European Caucasian PCa samples and its association with PCa risk. Methods Genotyping was conducted on 12 hormone-naïve aggressive PCa cultures (hnPCs) from untreated patients (Gleason ≥8), 11 radical prostatectomies (RP), and 94 serum samples using DNA Sanger sequencing and melting curve analysis. Comparative analysis utilized data from the GnomAD database's European Caucasian non-cancer population. Results Our results demonstrate a significantly higher frequency of the P72R SNP in PCa samples and serums compared to the general European non-cancer population. A robust and statistically significant association (p < 0.0001) between the SNP and prostate cancer risk was identified, with an odds ratio of 7.937 (95% CI 5.37-11.00). Notably, the G allele (R72) showed a pronounced prevalence in high Gleason score (≥8) patients, although statistical significance was not reached. These results highlight a potential association with undifferentiated and malignant PCa lesions. Conclusion The compelling association between the P72R SNP and prostate cancer risk underscores the potential utility of this marker for the early identification of patients at risk of aggressive metastatic prostate cancer. This insight could empower further research to intervene at an early stage by offering enhanced opportunities for timely and targeted interventions.
Collapse
Affiliation(s)
- Emily Toscano-Guerra
- Cell Signaling and Cancer Progression Laboratory, Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
- Clinical Biochemistry Department, Biochemistry Service, Vall d’Hebron Hospital, Barcelona, Spain
- Facultad Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Valentina Maggio
- Cell Signaling and Cancer Progression Laboratory, Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain
| | - Javier García
- Cell Signaling and Cancer Progression Laboratory, Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain
| | - Maria Eugenia Semidey
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
- Department of Pathology, Vall d’Hebron Hospital, Barcelona, Spain
| | - Ana Celma
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
- Department of Urology, Vall d’Hebron Hospital, Barcelona, Spain
| | - Juan Morote
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
- Department of Pathology, Vall d’Hebron Hospital, Barcelona, Spain
| | - Inés de Torres
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
- Department of Pathology, Vall d’Hebron Hospital, Barcelona, Spain
| | - Marina Giralt
- Clinical Biochemistry Department, Biochemistry Service, Vall d’Hebron Hospital, Barcelona, Spain
| | - Roser Ferrer-Costa
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
- Clinical Biochemistry Department, Biochemistry Service, Vall d’Hebron Hospital, Barcelona, Spain
| | - Rosanna Paciucci
- Cell Signaling and Cancer Progression Laboratory, Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
- Clinical Biochemistry Department, Biochemistry Service, Vall d’Hebron Hospital, Barcelona, Spain
| |
Collapse
|
2
|
Skhoun H, Khattab M, Belkhayat A, Takki Chebihi Z, Bakri Y, Dakka N, El Baghdadi J. Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children. Mol Biol Rep 2022; 49:8291-8300. [PMID: 35705773 DOI: 10.1007/s11033-022-07643-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Accepted: 05/25/2022] [Indexed: 10/18/2022]
Abstract
BACKGROUND TP53 gene plays a pivotal role in maintaining genetic stability and prevention of malignancies. Alterations of this gene are implicated in more than half of human cancers. To the best of our knowledge, this study is the first to explore TP53 polymorphisms in Moroccan childhood acute lymphoblastic leukemia (ALL). METHODS AND RESULTS DNA samples of 45 ALL children were obtained from peripheral blood. A total of 333 healthy Moroccans were used as controls. Polymerase chain reaction and Sanger sequencing were performed to analyze TP53 hotspot exons in cases. We identified a significant protective effect of the TP53-Arg variant at rs1042522 [OR 0.4593 (0.249-0.8472), p = 0.0127] and the Pro/Arg genotype [OR 0.0350 (0.0047-0.2583), p = 0.0010]. Additionally, we found a novel association between the C-allele of Arg213Arg 1800372 [OR 2.7736 (1.3821-5.5664), p = 0.0041] and the risk of childhood ALL. Importantly, TC/CC genotypes of this polymorphism were revealed to enhance the risk of ALL among females [OR 9.0 (3.1555-25.6693), p < 0.0001]. Arg213Arg was also noticed to be associated with the hemoglobin count of patients at diagnosis by linear regression (p = 0.0318). The analysis of penetrance showed a significant association of the CG/GG genotypes at rs1042522 and TC/CC genotypes at rs1800372 to childhood ALL via dominant model [OR 0.2090 (0.09074-0.4814), p = 0.0002 and OR 3.4205 (1.6084-7.2742), p = 0.0014 for rs1042522 and rs1800372 respectively]. No association was found between TP53 polymorphisms and patients survival. CONCLUSION Altogether, our findings indicated that TP53 polymorphisms are significantly involved in the genetic susceptibility to childhood ALL in Morocco.
Collapse
Affiliation(s)
- Hanaa Skhoun
- Genetics Unit, Military Hospital Mohammed V, Rabat, Morocco.,Laboratory of Human Pathologies Biology and Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - Mohammed Khattab
- Pediatric Hematology and Oncology Center, Children's Hospital, Rabat, Morocco
| | | | | | - Youssef Bakri
- Laboratory of Human Pathologies Biology and Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - Nadia Dakka
- Laboratory of Human Pathologies Biology and Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | | |
Collapse
|
3
|
Drokow EK, Chen Y, Waqas Ahmed HA, Oppong TB, Akpabla GS, Pei Y, Kumah MA, Neku EA, Sun K. The relationship between leukemia and TP53 gene codon Arg72Pro polymorphism: analysis in a multi-ethnic population. Future Oncol 2020; 16:923-937. [PMID: 32301350 DOI: 10.2217/fon-2019-0792] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: Many studies have analyzed the relationship between Arg72Pro polymorphism of TP53 and leukemia; nevertheless, the findings continue to be indeterminate. We, therefore, performed an updated meta-analysis in multi-ethnic groups using specialized software for genome-wide association studies meta-analysis. Materials & methods: PubMed, EMBASE and Google Scholar were searched up to October 2018. An odds ratio (OR) with the corresponding 95% CI was used to evaluate the strength in the association. Results: This meta-analysis included 16 studies with 2337 cases and 9494 controls. In the overall population, significant relationship between Arg72Pro polymorphism of TP53 and leukemia susceptibility was found in two genetic models (recessive model: OR = 1.276, 95% CI = 1.102-1.476; p = 0.01; overdominant model: OR = 0.891, 95% CI = 0.802-0.988; p = 0.03). In stratified studies with ethnicity, a significant association was found in five ethnic groups, including Chinese, Americans, Africans, Japanese and Indians. Conclusion: We demonstrated that an association exist between leukemia risk and TP53 gene codon Arg72Pro polymorphism in the recessive and overdominant genetic models. Also, our findings show that the TP53 Arg72Pro polymorphism may influence leukemia development in different populations.
Collapse
Affiliation(s)
- Emmanuel Kwateng Drokow
- Department of Radiation Oncology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, 450003 Zhengzhou, PR China
| | - Yuqing Chen
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, 450003 Zhengzhou, PR China
| | - Hafiz Abdul Waqas Ahmed
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, 450003 Zhengzhou, PR China
| | - Timothy Bonney Oppong
- Department of Epidemiology & Biostatistics, College of Public Health, Zhengzhou University, 450001 Zhengzhou, Henan, PR China
| | - Gloria Selorm Akpabla
- Department of Internal Medicine, Tianjin Medical University, 300070 Tianjin, PR China
| | - Yanru Pei
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, 450003 Zhengzhou, PR China
| | - Maame Awoyoe Kumah
- Department of Internal Medicine, University of Ghana Medical School, KB 77 Korle Bu, Accra, Ghana
| | - Enyonam Adjoa Neku
- Department of Pharmacy, Zhengzhou University, 450001 Zhengzhou, Henan, PR China
| | - Kai Sun
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, 450003 Zhengzhou, PR China
| |
Collapse
|
4
|
Voropaeva EN, Cherdyntseva NV, Voevoda MI, Pospelova TI, Maximov VN, Orlov YL, Ageeva TA. Triple Haplotypes of the TP53 Gene in Patients with Diffuse Small B-Cell Lymphoma. RUSS J GENET+ 2020. [DOI: 10.1134/s1022795419120123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
5
|
Mohammed Basabaeen AA, Abdelgader EA, Babekir EA, Abdelrahim SO, Eltayeb NH, Altayeb OA, Fadul EA, Sabo A, Ibrahim IK. TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population. Asian Pac J Cancer Prev 2019; 20:1579-1585. [PMID: 31128065 PMCID: PMC6857868 DOI: 10.31557/apjcp.2019.20.5.1579] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Objective:: This study aimed at exploring the association of TP53 72Arg/Pro polymorphism and Risk of Chronic Lymphocytic Leukemia and to assess the correlation between TP53 72Arg/Pro polymorphism and clinical parameter, hematological profile and some biological prognostic markers among Sudanese patients with chronic lymphocytic leukemia. Methods: A case-control study was conducted in Khartoum state, Sudan, during the period from April 2017 to April 2018, involved 110 B-CLL patients and 80 healthy volunteers as a control group. Physical examination, Complete Blood Count and Immunophenotype were performed in all patients to confirm the diagnosis. Clinical staging such as Rai and Binet were studied. CD38 and ZAP70 were performed by Flow Cytometry. Blood samples were collected from all participants; DNA was extracted by using ANALYTIKJENA Blood DNA Extraction Kit (Germany) and analyzed TP53 codon 72Arg/Pro Polymorphism by using AS-PCR. The statistical analysis was performed using SPSS version 23.0 software (Chicago, IL, USA). Results: the Arg/Pro was the most frequent genotype in B-CLL patients(50%), followed by Arg/Arg (25.5%) and Pro/Pro (24.5%), whereas in healthy control group Arg/Pro was the most frequent (47.5%), followed by Arg/Arg (45%) and Pro/Pro (7.5%). Our data indicate a higher frequency of homozygous Pro/Pro in the B-CLL patients as compared to controls with an OR of 4.01 for the Pro/Pro genotype and lower frequency of Arg/Arg genotype in CLL patients as compared to controls with an OR of .42 for the Arg/Arg genotype. Also, the Pro allele showed higher risk than Arg allele (P value=0.000, OR 2.23, 95% CI=1.45-3.41). No significant association between gender, clinical staging systems (Rai, Binet), biological prognostic markers (CD38 expression or ZAP70 expression), and TP53 codon 72Arg/Pro polymorphisms, except Arg/Arg genotype tended to be associated with younger age (P =0.04). Conclusion: Our data suggested that Pro/Pro genotype contribute to increased susceptibility to B-Chronic Lymphocytic Leukemia risk in our population tenfold higher than those had Arg/Arg genotype.
Collapse
Affiliation(s)
- Ameen Abdulaziz Mohammed Basabaeen
- Department of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.,Ministry of Health, Hadhramout, Yemen
| | | | - Ebtihal Ahmed Babekir
- Department of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan
| | - Saadia Osman Abdelrahim
- Department of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan
| | - Nada Hassan Eltayeb
- Department of Physiology, Faculty of Medicine, Al Neelain University, Khartoum, Sudan
| | - Osama Ali Altayeb
- Flow Cytometry Laboratory for Leukemia &Lymphoma Diagnosis, Khartoum, Sudan
| | - Eman Abbass Fadul
- Flow Cytometry Laboratory for Leukemia &Lymphoma Diagnosis, Khartoum, Sudan
| | - Abdulwali Sabo
- Department of Statistics, School of Medical Sciences, University Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia
| | - Ibrahim Khider Ibrahim
- Department of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.,Department of Hematology, School of Medical Sciences, University Sains Malaysia, Health Campus, Kubang Kerian, Kelantan, Malaysia
| |
Collapse
|
6
|
Hedayatizadeh-Omran A, Alizadeh-Navaei R, Janbabaei G, Omrani-Nava V, Hasheminasab Y, Amjadi O, Tehrani M. Association of P53 gene polymorphism with gastric cancer in Northern Iran as a high-risk region. Biomed Rep 2018; 8:433-438. [PMID: 29616139 PMCID: PMC5876468 DOI: 10.3892/br.2018.1070] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Accepted: 11/30/2017] [Indexed: 02/06/2023] Open
Abstract
Gastric cancer has the fourth highest morbidity rate of all cancers worldwide. Genetic factors including alterations in oncogenes and tumor suppressor genes serve an important role in gastric cancer development and progression. The P53 gene acts as a tumor suppressor gene by regulating the cell cycle, DNA transcription and repair, apoptosis, senescence and genome stability. In addition to somatic P53 mutations in cancer development, germline polymorphisms are also involved in different malignancies. The polymorphism of P53 at codon 72 (Arg72Pro) is established as a common variant that increases susceptibility to various cancers. The present case-control study was conducted to evaluate the possible association between this P53 polymorphism and gastric cancer in the Iranian population. A total of 59 patients with gastric cancer and 59 healthy controls were enrolled in the present study. Genomic DNA was extracted from peripheral blood mononuclear cells and genotype analysis was performed using a polymerase chain reaction-based restriction fragment length polymorphism assay. Genotype frequencies did not differ significantly between the patients and controls (P=0.4); the frequencies of the three genotypes Arg/Arg, Arg/Pro and Pro/Pro in gastric cancer patients were 28.8, 49.2 and 22.0%, and in controls were 37.3, 49.2 and 13.6%. Additionally, there were no differences in genotype frequencies based on tumor location, histological differentiation or tumor stage. Based on these findings, it may be concluded that the P53 codon 72 polymorphism does not contribute to gastric cancer susceptibility in Northern Iran.
Collapse
Affiliation(s)
- Akbar Hedayatizadeh-Omran
- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
| | - Reza Alizadeh-Navaei
- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
- Correspondence to: Dr Reza Alizadeh-Navaei, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran, E-mail:
| | - Ghasem Janbabaei
- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
| | - Versa Omrani-Nava
- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
| | - Yahya Hasheminasab
- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
| | - Omolbanin Amjadi
- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
| | - Mohsen Tehrani
- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48166-33131, Iran
| |
Collapse
|
7
|
TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP. BMC Cancer 2017; 17:743. [PMID: 29126407 PMCID: PMC5680759 DOI: 10.1186/s12885-017-3760-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 11/06/2017] [Indexed: 11/25/2022] Open
Abstract
Background TP53 Arg72Pro (SNP rs1042522) is associated with risk of non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. However, the relationship between this SNP and prognosis of DLBCL in Asians is unknown. Methods Genotyping of TP53 Arg72Pro was done in 425 Chinese DLBCL patients. Two hundred and eighty-nine patients were treated with R-CHOP, and 136 patients received CHOP or CHOP-like as frontline regimen. Three hundred and ninety-six patients were assessable for the efficacy. Results Patients with Arg/Arg and Arg/Pro at codon 72 of TP53 had a higher complete response rate (61% vs. 44%, P = 0.007) than those with Pro/Pro. In the subgroup treated with CHOP or CHOP-like therapy, patients with Arg/Arg and Arg/Pro showed a higher 5-year overall survival (OS) rate than those with Pro/Pro (68.8% vs. 23.2%, P = 0.001). Multivariate Cox regression analysis revealed TP53 Arg72 as a favorable prognostic factor in this group. However, the combination of rituximab with CHOP significantly increased the 5-year OS rate of patients with Pro/Pro to 63%. Conclusion This study revealed TP53 Arg72 as a favorable prognostic factor for Chinese DLBCL patients treated with CHOP or CHOP-like as frontline therapy.
Collapse
|
8
|
TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome. Blood Cells Mol Dis 2016; 59:129-33. [PMID: 27282582 DOI: 10.1016/j.bcmd.2016.05.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Revised: 05/10/2016] [Accepted: 05/10/2016] [Indexed: 12/19/2022]
Abstract
BCR-ABL1 gene is a key molecular marker of chronic myeloid leukemia (CML), but it is still unclear which molecular factors may influence CML risk or lead to variable responses to tyrosine kinase inhibitors (TKIs). The aim of this study was to investigate the impact of TP53 c.213 G>C(Arg72Pro; rs1042522) polymorphism on CML risk and its correlation with clinical outcome. Peripheral blood samples from 141 treated CML patients and 141 sex- and age-matched healthy individuals were genotyped by PCR-RFLP. Standard genetic models for disease penetrance were evaluated by logistic regression analysis and Kaplan-Meier method was performed to estimate survival curves. Our study suggests that TP53 c.213 G>C polymorphism may be involved in CML development considering a recessive model (p=0.01; OR: 0.19; CI: 0.06-0.68). In addition, a non-homogenous distribution was found for this polymorphism in males and patients youngers than 50years (p=0.02). According to clinical response, TP53-GG genotype was associated with higher levels of BCR-ABL1 transcripts (p=0.04) and shorter event free survival (p=0.04). Moreover, a trend toward significance was found for failure free survival (p=0.06) and time to imatinib failure (p=0.08). In conclusion, our data suggest that a;TP53 c.213 G>C may be a potential biomarker of CML susceptibility and clinical outcome.
Collapse
|
9
|
Tian X, Dai S, Sun J, Jiang S, Jiang Y. Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies. Sci Rep 2016; 6:24097. [PMID: 27053289 PMCID: PMC4823650 DOI: 10.1038/srep24097] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Accepted: 03/21/2016] [Indexed: 02/05/2023] Open
Abstract
The relationship between the TP53 Arg72Pro polymorphism (rs1042522) and the risk of leukemia remains controversial. Consequently, we performed a meta-analysis to accurately evaluate the association between TP53 Arg72Pro polymorphism and leukemia risk. A comprehensive search was conducted to find all eligible studies of TP53 Arg72Pro polymorphism and leukemia risk. Fourteen case-control studies, with 2,506 cases and 4,386 controls, were selected for analysis. The overall data failed to indicate a significant association between TP53 Arg72Pro polymorphism and the risk of leukemia (C vs. G: OR = 1.09, 95% CI = 0.93–1.26; CC vs. GC + GG: OR = 1.23, 95% CI = 0.96–1.57). In a subgroup analysis of clinical types, an increased risk was observed in the acute lymphocytic leukemia (ALL) subgroup (CC vs. GC + GG: OR = 1.73; 95% CI = 1.07–2.81) but not in the acute myeloid leukemia (AML) subgroup. In the subgroup analysis, no significant associations with ethnicity and the source of the controls were observed. In conclusion, the results suggest that there is no association between TP53 Arg72Pro polymorphism and the risk of leukemia, but the CC genotype may increase the risk of ALL TP53 Arg72Pro polymorphism CC genotype may increase the risk of ALL but is not associated with AML. Further large-scale, well-designed studies are needed to confirm our results.
Collapse
Affiliation(s)
- Xin Tian
- Molecular Oncology Laboratory of Cancer Research Institute, the First Affiliated Hospital of China Medical University, Shenyang, 110001, P.R. China
| | - Shundong Dai
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, 110001, P.R. China.,Institute of Pathology and Pathophysiology, Shenyang, 110001, P.R. China
| | - Jing Sun
- Department of Immunology and Biotherapy, Liaoning Cancer Hospital and Institute, Shenyang, 110042, P.R. China
| | - Shenyi Jiang
- Department of Rheumatology, the First Affiliated Hospital of China Medical University, Shenyang, 110001, P.R. China
| | - Youhong Jiang
- Molecular Oncology Laboratory of Cancer Research Institute, the First Affiliated Hospital of China Medical University, Shenyang, 110001, P.R. China
| |
Collapse
|
10
|
Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol 2016; 172:914-22. [PMID: 26771088 DOI: 10.1111/bjh.13912] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 10/30/2015] [Indexed: 12/22/2022]
Abstract
Treatment success in patients with acute myeloid leukaemia (AML) is heterogeneous. Cytogenetic and molecular alterations are strong prognostic factors, which have been used to individualize treatment. Here, we studied the impact of TP53 mutations on the outcome of AML patients with adverse cytogenetic risk treated with allogeneic haematopoietic stem cell transplantation (HSCT). Samples of 97 patients with AML and adverse-risk cytogenetics who had received a HSCT within three randomized trials were analysed. Complete sequencing of the TP53 coding region was performed using next generation sequencing. The median age was 51 years. Overall, TP53 mutations were found in 40 patients (41%). With a median follow up of 67 months, the three-year probabilities of overall survival (OS) and event-free survival for patients with TP53 wild type were 33% [95% confidence interval (CI), 21% to 45%] and 24% (95% CI, 13% to 35%) compared to 10% (95% CI, 0% to 19%) and 8% (95% CI, 0% to 16%) (P = 0·002 and P = 0·007) for those with mutated TP53, respectively. In multivariate analysis, the TP53-mutation status had a negative impact on OS (Hazard Ratio = 1·7; P = 0·066). Mutational analysis of TP53 might be an important additional tool to predict outcome after HSCT in patients with adverse karyotype AML.
Collapse
Affiliation(s)
- Jan M Middeke
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Sylvia Herold
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany.,Deutsches Konsortium für Translationale Krebsforschung Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany
| | - Elke Rücker-Braun
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Wolfgang E Berdel
- Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany
| | - Matthias Stelljes
- Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany
| | | | | | | | | | - Anthony D Ho
- Medizinische Klinik und Poliklinik, Abteilung Innere Medizin V, Hämatologie, Onkologie und Rheumatologie, Universität Heidelberg, Heidelberg, Germany
| | - Hermann Einsele
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - Wolf Rösler
- Medizinische Klinik 5, Universitätsklinikum Erlangen, Erlangen, Germany
| | - Hubert Serve
- Medizinische Klinik II, Klinikum der J.W. Goethe Universität, Frankfurt, Germany
| | - Mathias Hänel
- Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Chemnitz, Germany
| | - Kristina Sohlbach
- Kliniken für Innere Medizin, Hämatologie/Onkologie und Immunologie, Universitätsklinikum Marburg, Marburg, Germany
| | - Christian Klesse
- DKMS German Bone Marrow Donor Centre, Clinical Trials Unit, Dresden, Germany
| | - Brigitte Mohr
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Falk Heidenreich
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Friedrich Stölzel
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Christoph Röllig
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Uwe Platzbecker
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Gerhard Ehninger
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Martin Bornhäuser
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
| | - Christian Thiede
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany.,Deutsches Konsortium für Translationale Krebsforschung Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany
| | - Johannes Schetelig
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany.,DKMS German Bone Marrow Donor Centre, Clinical Trials Unit, Dresden, Germany
| | | |
Collapse
|
11
|
Ruan XL, Li S, Meng XY, Geng P, Gao QP, Ao XB. The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94:e1588. [PMID: 26402821 PMCID: PMC4635761 DOI: 10.1097/md.0000000000001588] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
The purpose of this meta-analysis was aimed to evaluate the association of tumor protein p53 (TP53) gene codon 72 polymorphism with leukemia susceptibility. We searched PubMed to identify relevant studies, and 16 case-control studies from 14 published articles were identified as eligible studies, including 2062 leukemia patients and 5826 controls. After extracting data, odds ratio (OR) with the corresponding 95% confidence interval (95%CI) was applied to assess the association between TP53 codon 72 polymorphism and leukemia susceptibility. The meta-analysis was performed with the Comprehensive Meta-Analysis software, version 2.2. Overall, no significant association between TP53 codon 72 polymorphism and leukemia susceptibility was found in this meta-analysis (Pro vs Arg: OR = 1.05, 95%CI = 0.90-1.21; Pro/Pro vs Arg/Arg: OR = 1.13, 95%CI = 0.84-1.52; Arg/Pro vs Arg/Arg: OR = 0.94, 95%CI = 0.76-1.15; [Pro/Pro + Arg/Pro] vs Arg/Arg: OR = 0.99, 95%CI = 0.80-1.21; Pro/Pro vs [Arg/Arg + Arg/Pro]: OR = 1.19, 95%CI = 0.93-1.51). Similar results were also found in subgroup analysis by ethnicity, source of controls, and types of leukemia (either acute myeloid leukemia or acute lymphocytic leukemia). Our meta-analysis demonstrates that TP53 codon 72 polymorphism may not be a risk factor for acute leukemia; however, due to the limitations of this study, it should be verified in future studies.
Collapse
Affiliation(s)
- Xiao-Lan Ruan
- From the Department of Hematology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China (X-LR, QPG, X-BA); Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province 430022, China (SL, X-YM, PG); and Center for Evidence-Based and Translational Medicine, Wuhan University, Wuhan, Hubei Province 430022, China (SL, X-YM, PG)
| | | | | | | | | | | |
Collapse
|
12
|
Sergentanis TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, Dimopoulos MA, Psaltopoulou T. Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2015; 15:563-77.e1-3. [PMID: 26294217 DOI: 10.1016/j.clml.2015.06.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 06/12/2015] [Indexed: 11/30/2022]
Abstract
The epidemiology of multiple myeloma (MM) is an increasingly investigated field, with many controversies. This systematic review aims to synthesize meta-analyses examining risk factors for MM so as to provide a comprehensive, parsimonious summary of the current evidence. Eligible meta-analyses were sought in PubMed adopting a predefined algorithm, without any restriction of publication language; end-of-search date was October 10, 2014. The selection of eligible studies and data extraction were performed by working in pairs, independently and blindly to each other; in case of disagreement, consensus with the whole team was reached. Among the 22 ultimately included meta-analyses, 9 examined occupational factors, 4 assessed aspects of lifestyle (smoking, alcohol, body mass index), 5 evaluated the presence of other diseases, and 4 addressed genetic factors as potential risk factors of MM. A vast compendium of significant associations arose, including farming, occupation as a firefighter, occupation as a hairdresser, exposures to chemicals or pesticides, overweight and obesity, patterns of alcohol intake, pernicious anemia, ankylosing spondylitis, gene promoter methylation, and polymorphisms. In conclusion, MM is a multifactorial disease, encompassing a wide variety of risk factors that span numerous life aspects. Further accumulation of evidence through meta-analyses is anticipated in this rapidly growing field.
Collapse
Affiliation(s)
- Theodoros N Sergentanis
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Flora Zagouri
- Department of Clinical Therapeutics, "Alexandra" Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Gerasimos Tsilimidos
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Anastasia Tsagianni
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Melina Tseliou
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Meletios A Dimopoulos
- Department of Clinical Therapeutics, "Alexandra" Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
| | - Theodora Psaltopoulou
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
13
|
Du L, Liu Y, Xue P, Song C, Shen J, He Q, Peng Y, Tong X, Tang L, Zhang Y. The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies. Tumour Biol 2015; 36:4545-54. [DOI: 10.1007/s13277-015-3099-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 01/03/2014] [Indexed: 12/11/2022] Open
|
14
|
Malakar M, Devi KR, Phukan RK, Kaur T, Deka M, Puia L, Sailo L, Lalhmangaihi T, Barua D, Rajguru SK, Mahanta J, Narain K. p53 codon 72 polymorphism interactions with dietary and tobacco related habits and risk of stomach cancer in Mizoram, India. Asian Pac J Cancer Prev 2014; 15:717-23. [PMID: 24568485 DOI: 10.7314/apjcp.2014.15.2.717] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND This study was carried out to investigate the interaction of p53 codon 72 polymorphism, dietary and tobacco habits with reference to risk of stomach cancer in Mizoram, India. A total of 105 histologically confirmed stomach cancer cases and 210 age, sex and ethnicity matched healthy population controls were included in this study. MATERIALS AND METHODS The p53 codon 72 polymorphism was detected by PCR-RFLP and sequencing. H. pylori infection status was determined by ELISA. Information on various dietary and tobacco related habits was recorded with a standard questionnaire. RESULTS This study revealed that overall, the Pro/ Pro genotype was significantly associated with a higher risk of stomach cancer (OR, 2.54; 95%CI, 1.01-6.40) as compared to the Arg/Arg genotype. In gender stratified analysis, the Pro/Pro genotype showed higher risk (OR, 7.50; 95%CI, 1.20-47.0) than the Arg/Arg genotype among females. Similarly, the Pro/Pro genotype demonstrated higher risk of stomach cancer (OR, 6.30; 95%CI, 1.41-28.2) among older people (>60 years). However, no such associations were observed in males and in individuals <60 years of age. Smoke dried fish and preserved meat (smoke dried/sun dried) consumers were at increased risk of stomach cancer (OR, 4.85; 95%CI, 1.91-12.3 and OR, 4.22; 95%CI, 1.46-12.2 respectively) as compared to non-consumers. Significant gene-environment interactions exist in terms of p53 codon 72 polymorphism and stomach cancer in Mizoram. Tobacco smokers with Pro/Pro and Arg/Pro genotypes were at higher risk of stomach cancer (OR, 16.2; 95%CI, 1.72-153.4 and OR, 9.45; 95%CI, 1.09-81.7 respectively) than the non-smokers Arg/Arg genotype carriers. The combination of tuibur user and Arg/Pro genotype also demonstrated an elevated risk association (OR, 4.76; 95%CI, 1.40-16.21). CONCLUSIONS In conclusion, this study revealed that p53 codon 72 polymorphism and dietary and tobacco habit interactions influence stomach cancer development in Mizoram, India.
Collapse
Affiliation(s)
- Mridul Malakar
- Regional Medical Research Centre, NE Region (Indian Council of Medical Research), Dibrugarh, India E-mail :
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Voropaeva EN, Voevoda MI, Pospelova TI, Maksimov VN. Linkage disequilibrium and haplotypes of the rs1042522, rs1625895, and rs1787862 markers of TP53 in patients with diffuse large B-cell lymphoma. Mol Biol 2014. [DOI: 10.1134/s0026893314050173] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
16
|
Panni S, Salvioli S, Santonico E, Langone F, Storino F, Altilia S, Franceschi C, Cesareni G, Castagnoli L. The adapter protein CD2AP binds to p53 protein in the cytoplasm and can discriminate its polymorphic variants P72R. J Biochem 2014; 157:101-11. [PMID: 25261582 DOI: 10.1093/jb/mvu059] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Proline-rich motifs are widely distributed in eukaryotic proteomes and are usually involved in the assembly of functional complexes through interaction with specific binding modules. The tumour-suppressor p53 protein presents a proline-rich region that is crucial for regulating apoptosis by connecting the p53 with a complex protein network. In humans, a common polymorphism determines the identity of residue 72, either proline or arginine, and affects the features of the motifs present in the polyproline domain. The two isoforms have different biochemical properties and markedly influence cancer onset and progression. In this article, we analyse the binding of the p53 proline-rich region with a pool of selected polyproline binding domains (i.e. SH3 and WW), and we present the first demonstration that the purified SH3 domains of the CD2AP/Cin85 protein family are able to directly bind the p53 protein, and to discriminate between the two polymorphic variants P72R.
Collapse
Affiliation(s)
- Simona Panni
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Stefano Salvioli
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Elena Santonico
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Francesca Langone
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Francesca Storino
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Serena Altilia
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Claudio Franceschi
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Gianni Cesareni
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| | - Luisa Castagnoli
- Department DiBEST, University of Calabria, Rende, 87036, Italy; DIMES, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy; CIG, Interdepartmental Center "Luigi Galvani", University of Bologna, Bologna 40126, Italy; Department of Biology, University of Rome Tor Vergata, Rome 00100, Italy; and Istituto Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Rome, 00100, Italy
| |
Collapse
|
17
|
Fan C, Wei J, Yuan C, Wang X, Jiang C, Zhou C, Yang M. The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk. PLoS One 2014; 9:e107047. [PMID: 25203442 PMCID: PMC4159297 DOI: 10.1371/journal.pone.0107047] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Accepted: 08/06/2014] [Indexed: 11/18/2022] Open
Abstract
As a heterogeneous kind of malignances, Non-Hodgkin lymphoma (NHL) is the most common hematologic cancer worldwide with the significantly increased morbidity in China. Accumulated evidences demonstrated that oncoprotein MDM4 plays a crucial role in the TP53 tumor suppressor signaling pathway. An rs4245739 A>C polymorphism locating in the MDM4 3′-untranslated region creates a miR-191 target site and results in allele-specific MDM4 expression. In this study, we examined the association between this polymorphism as well as the TP53 Arg72Pro (rs1042522 G>C) genetic variant and Non-Hodgkin Lymphoma (NHL) risk in a Chinese Han population. Genotypes were determined in 200 NHL cases and 400 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression. We found significantly increased NHL risk among carriers of the TP53 72Pro allele compared with those with the 72Arg allele (P = 0.002 for the Pro/Pro genotype). We also observed a significantly decreased NHL risks among carriers of the MDM4 rs4245739 C allele compared with those with the A allele in Chinese (P = 0.014 for the AC genotype). Stratified analyses revealed the associations between these SNPs and NHL risk are especially noteworthy in young or male individuals. Additionally, the associations are much pronounced in NHL patients with B-cell lymphomas or grade 3 or 4 disease. Our results indicate that the TP53 Arg72Pro and the MDM4 rs4245739 polymorphisms contribute to NHL susceptibility and support the hypothesis that genetic variants in the TP53 pathway genes can act as important modifiers of NHL risk.
Collapse
Affiliation(s)
- Chuanbo Fan
- Department of Hematology, Shandong Provincial Hospital of Shandong University, Jinan, Shandong Province, China
- Department of Hematology, Qingdao Hiser Medical Center, Qingdao, Shandong Province, China
| | - Jinyu Wei
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Chenglu Yuan
- Department of Hematology, Qilu Hospital of Shandong University, Qingdao, Shandong Province, China
| | - Xin Wang
- Department of Hematology, Shandong Provincial Hospital of Shandong University, Jinan, Shandong Province, China
| | - Chuanwu Jiang
- Department of Radiology, Qingdao Hiser Medical Center, Qingdao, Shandong Province, China
| | - Changchun Zhou
- Clinical Laboratory, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China
- * E-mail: (MY); (CZ)
| | - Ming Yang
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
- * E-mail: (MY); (CZ)
| |
Collapse
|
18
|
No evidence of correlation between p53 codon 72 G > C gene polymorphism and cancer risk in Indian population: a meta-analysis. Tumour Biol 2014; 35:8607-13. [DOI: 10.1007/s13277-014-2114-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Accepted: 05/15/2014] [Indexed: 01/08/2023] Open
|
19
|
Liu L, Zhang D, Jiao JH, Wang Y, Wu JY, Huang DS. Association between the TP53BP1 rs2602141 A/C Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2014; 15:2917-22. [DOI: 10.7314/apjcp.2014.15.6.2917] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
20
|
Hattori Y, Ikeda Y, Suzuki Y, Ichikawa D, Matsushita M. Codon 72 polymorphism of TP53 gene is a novel prognostic marker for therapy in multiple myeloma. Br J Haematol 2014; 165:728-31. [PMID: 24611901 DOI: 10.1111/bjh.12784] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yutaka Hattori
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.
| | | | | | | | | |
Collapse
|
21
|
Liu L, Jiao J, Wang Y, Zhang D, Wu J, Huang D. Lack of association of the TP53BP1 Glu353Asp polymorphism with risk of cancer: a systematic review and meta-analysis. PLoS One 2014; 9:e90931. [PMID: 24603722 PMCID: PMC3946247 DOI: 10.1371/journal.pone.0090931] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2013] [Accepted: 02/04/2014] [Indexed: 11/19/2022] Open
Abstract
Objective The TP53BP1 gene may be involved in the development of cancer through disrupting DNA repair. However, studies investigating the relationship between TP53BP1 Glu353Asp (rs560191) polymorphism and cancer yielded contradictory and inconclusive outcomes. In order to realize these ambiguous findings, a meta-analysis was performed to assess the association between the TP53BP1 Glu353Asp (rs560191) polymorphism and susceptibility to cancer. Methods We conducted a search of all English reports on studies for the association between the TP53BP1 Asp353Glu (rs560191) polymorphism and susceptibility to cancer using Medline, the Cochrane Library, EMbase, Web of Science, Google (scholar), and all Chinese reports were identified manually and on-line using CBMDisc, Chongqing VIP database, and CNKI database. The strict selection criteria and exclusion criteria were determined, and odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. The fixed or random effect model was selected based on the heterogeneity test among studies. Publication bias was estimated using funnel plots and Egger’s regression test. Results A total of seven studies were included in the meta-analysis including 3,213 cases and 3,849 controls. The results indicated that the Glu353Asp (rs560191) polymorphism in TP53BP1 gene had no association with cancer risk for all genetic models. In the subgroup analysis, the results suggested that Glu353Asp polymorphism was not associated with the risk of cancer according to ethnicity, cancer type, genotyping method, adjusted with control or not, HWE and quality score. Conclusions This meta-analysis suggested that the Glu353Asp (rs560191) polymorphism in TP53BP1 gene was not associated with risk of cancer.
Collapse
Affiliation(s)
- Lei Liu
- Department of Ophthalmology, The First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang City, Liaoning Province, China
- * E-mail:
| | - Jinghua Jiao
- Department of Anesthesiology, Fengtian Hospital, Shenyang Medical College, Shenyang City, Liaoning Province, China
| | - Yu Wang
- Department of Development and Planning office, China Medical University, Shenyang City, Liaoning Province, China
| | - Dong Zhang
- Department of General Surgery, the Fourth People’s Hospital of Shenyang, Shenyang City, Liaoning Province, China
| | - Jingyang Wu
- Department of Ophthalmology, The First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China
| | - Desheng Huang
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang City, Liaoning Province, China
| |
Collapse
|
22
|
Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies. Tumour Biol 2014; 35:3009-16. [DOI: 10.1007/s13277-013-1388-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Accepted: 11/05/2013] [Indexed: 10/25/2022] Open
|
23
|
Ozbas-Gerceker F, Bozman N, Kok S, Pehlivan M, Yilmaz M, Pehlivan S, Oguzkan-Balci S. Association of an LMP2 Polymorphism with Acute Myeloid Leukemia and Multiple Myeloma. Asian Pac J Cancer Prev 2013; 14:6399-402. [DOI: 10.7314/apjcp.2013.14.11.6399] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
24
|
Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013; 2:e71. [PMID: 24042735 PMCID: PMC3816225 DOI: 10.1038/oncsis.2013.35] [Citation(s) in RCA: 622] [Impact Index Per Article: 56.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2013] [Accepted: 07/29/2013] [Indexed: 12/12/2022] Open
Abstract
Cell lines are invaluable biomedical research tools, and recent literature has emphasized the importance of genotype authentication and characterization. In the present study, 24 out of 27 cell line identities were confirmed by short tandem repeat profiling. The molecular phenotypes of the 24 colon cancer cell lines were examined, and microsatellite instability (MSI) and CpG island methylator phenotype (CIMP) were determined, using the Bethesda panel mononucleotide repeat loci and two epimarker panels, respectively. Furthermore, the BRAF, KRAS and PIK3CA oncogenes were analyzed for mutations in known hotspots, while the entire coding sequences of the PTEN and TP53 tumor suppressors were investigated. Nine cell lines showed MSI. Thirteen and nine cell lines were found to be CIMP positive, using the Issa panel and the Weisenberger et al. panel, respectively. The latter was found to be superior for CIMP classification of colon cancer cell lines. Seventeen cell lines harbored disrupting TP53 mutations. Altogether, 20/24 cell lines had the mitogen-activated protein kinase pathway activating mutually exclusive KRAS or BRAF mutations. PIK3CA and PTEN mutations leading to hyperactivation of the phosphoinositide 3-kinase/AKT pathway were observed in 13/24 cell lines. Interestingly, in four cell lines there were no mutations in neither BRAF, KRAS, PIK3CA nor in PTEN. In conclusion, this study presents molecular features of a large number of colon cancer cell lines to aid the selection of suitable in vitro models for descriptive and functional research.
Collapse
|
25
|
Wu B, Guo D, Guo Y. Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis. Tumour Biol 2013; 35:561-5. [DOI: 10.1007/s13277-013-1078-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2013] [Accepted: 08/05/2013] [Indexed: 12/20/2022] Open
|
26
|
P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects. Tumour Biol 2013; 34:2961-9. [DOI: 10.1007/s13277-013-0859-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 05/10/2013] [Indexed: 01/12/2023] Open
|